Abstract: The invention relates generally to compositions and methods for the detection of zinc. Provided herein is a class of zinc-responsive probes with tunable photophysical properties that can be modified for coupling to a solid support or other chemical moieties. In particular, modifications to the 5-position of the BODIPY core allows for alteration of probe properties and functionalities.

Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.

Abstract: An organic electroluminescence device in which a polycyclic compound including an electron donor and an electron acceptor is included in an emission layer is provided. The electron donor contains an acridine derivative or a dibenzo-azasiline derivative, and the electron acceptor contains B as a ring-forming atom, O or S directly bonded to B, and a heterocyclic group in which three or five hexagonal rings are condensed. Accordingly, an organic electroluminescence device having high efficiency may be achieved.

Abstract: By providing a novel polycyclic aromatic compound in which a plurality of aromatic rings is linked via a nitrogen atom, a boron atom, or the like, options of a material for an organic EL element are increased. In addition, by using the novel polycyclic aromatic compound as a material for an organic electroluminescent element, an excellent organic EL element is provided.

Abstract: A photoelectric conversion element according to the disclosure includes: a first electrode and a second electrode that are disposed to face each other; and a photoelectric conversion layer that is provided between the first electrode and the second electrode, and contains at least one kind of polycyclic aromatic compound represented by any one of the following general formula (1), the following general formula (2), and the following general formula (3):

Abstract: Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane selected to successively bring about reduction, deamination, and decarboxylation of oxidized 5-methylcytosine residues such as 5-carboxylcytosine and 5-formylcytosine, resulting in DHU residues in place thereof. Following amplification, the treated cell-free DNA is sequenced, with the DHU residues read as thymine residues. Reaction mixtures, kits and additional methods are also provided, as are related methods for the epigenetic analysis of DNA, including cell-free DNA.

Abstract: Provided herein is a process for preparing triaryl organoborates of the formula 1/n Kn+R34B?—R1 (IV), where one equivalent of organoboronic ester of the formula B—R1(OR2)(OR3) (I) is initially charged together with 1/n equivalents of salt Kn+ nX? (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1, 3 equivalents of a haloaromatic R4—Y (III) are added, an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n Kn+ R34B?—R1 (IV) is separated off with the organic phase, and to the use of these substances as co-initiator in photopolymer formulations.

Abstract: Provided herein is a process for preparing triaryl organoborates proceeding from alkyl or cycloalkyl boronates in the presence of an n-valent cation 1/n Kn+ to obtain organoborates of the formula 1/n Kn+R34B?—R1 (IV), where one equivalent of organoboronic ester of the formula B—R1(OR2)(OR3) (I) is initially charged together with 1/n equivalents of salt Kn+ nX? (II) and 3 equivalents of metal M in a solvent or a solvent mixture, 3 equivalents of a haloaromatic R4—Y (III) are added, and optionally a second organic solvent water is added and the compound 1/n Kn+ R24B?—R1 (IV) is separated off with the organic phase, and to the use of these substances as co-initiator in photopolymer formulations.

Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.

Abstract: The invention provides a compound of formula (I): or a salt thereof, wherein R1 and R2 have any of the values defined in the specification, as well as methods of using such compounds and salts to separate an aryl compound from a mixture.

Abstract: The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.

Abstract: The present invention relates to azaborinine derivatives their synthesis as well as their use in organic electronic devices, particularly in organic light emitting devices, organic photovoltaic devices and organic photodetectors.

Abstract: Precatalysts and catalytic processes for the functionalization of sp2-carbons using the precatalysts are described herein. The precatalysts comprise an intramolecular Frustrated Lewis Pair (FLP) that is generated in situ from the corresponding precatalyst fluoroborate salts. The precatalyst fluoroborate salts are deprotected in situ to generate catalysts including intramolecular FLPs for the dehydrogenative borylation of alkenes, arenes and heteroarenes. The catalytic process comprises contacting a precatalyst, a functionalization reagent; and a substrate comprising a sp2-H carbon, under conditions to provide a substrate comprising a functionalized sp2 carbon.

Abstract: Described herein are boron-containing precursor compounds, and compositions and methods comprising same, for forming boron-containing films. In one aspect, the film is deposited from at least one precursor having the following Formula I or II described herein.

Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.

Abstract: The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).

Abstract: The present invention relates to novel full-color tunable light emitter based on N,C-chelate four-coordinate organoborons having excellent Quantum yield, stokes shift and solvate chromism of Formula (I);

Abstract: The present invention relates to a process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters thereof of formula (I) in high yields starting from a dialkyl ketal derivative of formula (V)

Abstract: Disclosed herein is the preparation of functional group containing amine-boranes from the corresponding amines. The mild reaction conditions allow for the direct preparation of several hitherto inaccessible amine-boranes containing a functional moiety, such as but not limited to, alkene, alkyne, hydroxyl, thiol, acetal, ester, amide, nitrile, nitro, and alkoxysilane.

Abstract: A compound may be represented by Chemical Formula 1, an organic photoelectronic device may include a first electrode and a second electrode facing each other with an active layer that includes the compound represented by Chemical Formula 1 between the first electrode and the second electrode, and an image sensor may include the organic photoelectronic device.

Abstract: Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.

Abstract: The invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. The present invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. On certain substrates and under specific reaction conditions, the inventors have discovered that the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis surprisingly provides for a more active and efficient process as compared to mono-quarternary catalysts.

Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

Abstract: A method for production of hydroxycarboxylic acid amide compounds, including performing amide condensation between an ?- or ?-hydroxycarboxylic acid compound and an amine compound in the presence as a catalyst of an alkylboronic acid represented by R3B(OH)2 (wherein R3 is a primary alkyl group) or an arylboronic acid compound to produce a hydroxycarboxylic acid amide compound, the arylboronic acid compound being represented by Formula (1): (in Formula (1), —(CH2)nNR1R2 is bonded at an ortho position or a para position, n is 1 or 2, R1 is a tertiary alkyl group, R2 is a secondary or tertiary alkyl group, and —NR1R2 may be a ring).

Abstract: Herein are disclosed fluorescent dyes based around a framework for a ligand comprising a pyridyl group linked to a diaryl anilido unit. A variety of ligands based on this framework are disclosed. The ligands chelate to a BF2 center to produce the fluorescent dye. The disclosed dyes combine longer Stokes shifts (approximately 100 nm) with increased quantum yields. They are also photostable in aqueous and organic solutions for several hours. These dyes may be used in the labeling of biomolecules for bioimaging and assays. Also disclosed are methods for the synthesis of these dyes.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Abstract: This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Abstract: The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes a diversity element which potentially binds to a target molecule with a dissociation constant of less than 300 ?M and a linker element connected to the diversity element. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to said diversity element, and is capable of forming a reversible covalent bond or non-covalent interaction with a binding partner of the linker element. The monomers can be covalently or non-covalently linked together to form a therapeutic multimer or a precursor thereof. Also disclosed is a method of screening for therapeutic multimer precursors which bind to a target molecule associated with a condition and a method of screening for linker elements capable of binding to one another.

Abstract: Provided is an organic electroluminescent element which has improved driving voltage and improved current efficiency. An organic electroluminescent element having the above-mentioned improved characteristics is provided by using, as a material for organic electroluminescent elements, a polycyclic aromatic compound in which a nitrogen atom and another heteroatom or a metal atom (X) are adjacent to each other in a non-aromatic ring.

Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK).

Abstract: A borate moiety-contained linker and a bio-sensing element containing the same are disclosed. The borate moiety-contained linker can be used to modify a sensing molecule and connect the sensing molecule to a substrate to form the bio-sensing element.

Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.

Abstract: The invention relates generally to compositions and methods for the detection of zinc. In particular, compositions and methods are provided to detect changes in cellular zinc concentration and to correlate them to cellular phenomena.

Abstract: The present invention relates to novel cluster boron compounds and their use as sodium channel blockers. In particular, the novel cluster boron compounds may be lidocaine analogs where the aromatic ring of the lidocaine molecule is replaced with a cluster boron group. The invention also provides methods for making the cluster boron compounds comprising contacting a halogenated cluster boron with an amino acetamide in the presence of a catalyst, a proton acceptor, and a ligand.

Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

Abstract: A compound comprising a boron subphthalocyanine moiety, a plurality of solubilizing substituents positioned on peripheral cyclic groups of the boron subphthalocyanine moiety and an axial substituent positioned on the boron atom. The plurality of solubilizing substituents comprise an oxygen or sulfur containing functional group and a substituted or unsubstituted, linear, branched or cyclic, aliphatic or aromatic terminal hydrocarbyl group that is 8 or more carbon atoms in length, the hydrocarbyl group optionally containing one or more heteroatoms. The axial substituent is a cyclic group selected from the group consisting of heterocyclic amine groups, diaryl ketone groups, benzotriazole groups, benzyl alcohol groups and polycyclic aromatic hydrocarbon groups, the cyclic group being bonded to the boron atom by an oxygen containing linking moiety, the cyclic group optionally being substituted with one or more additional substituents.

Abstract: A method for production of hydroxycarboxylic acid amide compounds, including performing amide condensation between an ?- or ?-hydroxycarboxylic acid compound and an amine compound in the presence as a catalyst of an alkylboronic acid represented by R3B(OH)2 (wherein R3 is a primary alkyl group) or an arylboronic acid compound to produce a hydroxycarboxylic acid amide compound, the arylboronic acid compound being represented by Formula (1): (in Formula (1), —(CH2)nNR1R2 is bonded at an ortho position or a para position, n is 1 or 2, R1 is a tertiary alkyl group, R2 is a secondary or tertiary alkyl group, and —NR1R2 may be a ring).

Abstract: The invention relates to a process for the preparation of alkali-metal salts with dihydridodicyanoborate anions by reaction of alkali-metal tetrahydridoborates or trihydridocyanoborates with trialkylsilyl cyanide and further reaction thereof in metathesis reactions.

Abstract: Aromatic heterocycles incorporating boron and nitrogen atoms, in particular, 1,2-azaborine compounds having the formula and their use as synthetic intermediates.

Abstract: Disclosed are hypergolic salts with borane cluster anions that ignite spontaneously upon contact with nitric acid (from 70% to 100% in water) with short ignition delay. The salts, when added as trigger additive to combustible solvent or ionic liquids, make the resulting formulation hypergolic. The salts with borane cluster anions also shorten ignition delay in hypergols, such as RP-1, and additionally allow nitric acid to be used to replace liquid oxygen as an oxidizer. In some examples, the borane salts are formed in situ in an ionic liquid.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

Abstract: The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases.

Abstract: Boron-comprising perylene monoimides and a process for producing the boron-comprising perylene monoimides are provided. The boron-comprising perylene monoimides are useful as building blocks for producing perylene monoimide derivatives and monoimide derivatives. The boron-comprising perylene monoimides are also useful for preparing dye-sensitized solar cells.

Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of Arginase I and II activity. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the inventive compounds for treating or preventing a disease or a condition associated with arginase activity.

Abstract: The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands.

Abstract: Provided is an organic electroluminescent device (organic EL device) with improved luminous efficiency, sufficiently ensured driving stability, and a simple construction. The organic electroluminescent device includes an anode, an organic layer, and a cathode laminated on a substrate, in which at least one organic layer selected from the group consisting of a light-emitting layer, a hole-transporting layer, an electron-transporting layer, an electron-blocking layer, and a hole-blocking layer contains a carborane compound that has at least one carborane ring with a silyl group on the carbon thereof.

Abstract: The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Abstract: The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.